
    
      1. To evaluate the safety and tolerability of Henatinib, and the maximum tolerated dose
           (MTD) and dose-limiting toxicity (DLT).

        2. To determine the pharmacokinetic profile of Henatinib and its metabolites .

        3. To assess preliminary antitumor activity .

        4. To determine preliminary regimen for phase II study .
    
  